Delving into the Latest Updates on Hainan Brilliant Pharmaceutical Co., Ltd. with Synapse

Overview

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Biological products	1
Recombinant polypeptide	1
Biosimilar	1

Top 5 Target	Count

GLP-1R(Glucagon-like peptide 1 receptor)	1

主要研究目的：评估司美格鲁肽注射液和WEGOVY®在肥胖成年患者中作为生活方式干预辅助治疗的疗效相似性。次要研究目的：评估司美格鲁肽注射液和WEGOVY®在肥胖成年患者中作为生活方式干预辅助治疗的安全性。评估司美格鲁肽注射液的免疫原性。

[Translation]

Primary study objective: To evaluate the similarity of the efficacy of semaglutide injection and WEGOVY® as adjuncts to lifestyle intervention in obese adult patients. Secondary study objectives: To evaluate the safety of semaglutide injection and WEGOVY® as adjuncts to lifestyle intervention in obese adult patients. To evaluate the immunogenicity of semaglutide injection.

Start Date23 Oct 2024

Sponsor / Collaborator

Chengdu Brilliant Pharmaceutical Company

CTR20241464

/ CompletedNot Applicable

达格列净片在健康受试者中的单剂量、空腹和餐后、随机、开放、两周期、两交叉生物等效性研究

[Translation] A single-dose, fasting and fed, randomized, open-label, two-period, two-crossover bioequivalence study of dapagliflozin tablets in healthy subjects

主要研究目的：本研究以海南倍康医药科技有限公司持有的达格列净片（10mg）为受试制剂，以AstraZeneca AB公司持有的原研进口达格列净片（10mg，商品名：安达唐®）为参比制剂，评价受试制剂和参比制剂在空腹和餐后条件下给药时的生物等效性。次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main research purpose: This study uses dapagliflozin tablets (10 mg) held by Hainan Beikang Pharmaceutical Technology Co., Ltd. as the test preparation and the original imported dapagliflozin tablets (10 mg, trade name: Andatang®) held by AstraZeneca AB as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions. Secondary research purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date18 May 2024

Sponsor / Collaborator

Hainan Beikang Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Hainan Brilliant Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hainan Brilliant Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Hainan Brilliant Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hainan Brilliant Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Phase 3

Login to view more data